Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Accumulated Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Accumulated Expenses for 8 consecutive years, with $60.0 million as the latest value for Q1 2026.

  • Quarterly Accumulated Expenses rose 35.14% to $60.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $60.0 million through Feb 2026, up 35.14% year-over-year, with the annual reading at $54.9 million for FY2025, 44.37% up from the prior year.
  • Accumulated Expenses for Q1 2026 was $60.0 million at Nurix Therapeutics, up from $54.9 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $60.0 million in Q1 2026, with the low at $7.9 million in Q2 2022.
  • Average Accumulated Expenses over 5 years is $29.4 million, with a median of $25.0 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses increased 2.32% in 2022, then surged 130.28% in 2023.
  • Over 5 years, Accumulated Expenses stood at $22.4 million in 2022, then increased by 11.33% to $25.0 million in 2023, then skyrocketed by 52.16% to $38.0 million in 2024, then surged by 44.37% to $54.9 million in 2025, then rose by 9.29% to $60.0 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $60.0 million, $54.9 million, and $44.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.